Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
131,516,365
-
Number of holders
-
395
-
Total 13F shares, excl. options
-
111,604,687
-
Shares change
-
-835,064
-
Total reported value, excl. options
-
$21,068,206,424
-
Value change
-
-$147,043,437
-
Put/Call ratio
-
44%
-
Number of buys
-
196
-
Number of sells
-
-158
-
Price
-
$188.81
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2021
474 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2021.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 395 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111,604,687 shares
of 131,516,365 outstanding shares and own 84.86% of the company stock.
Largest 10 shareholders include FMR LLC (17,826,928 shares), VANGUARD GROUP INC (10,614,582 shares), BAILLIE GIFFORD & CO (10,415,784 shares), BlackRock Inc. (8,920,972 shares), WELLINGTON MANAGEMENT GROUP LLP (7,371,072 shares), PRICE T ROWE ASSOCIATES INC /MD/ (5,874,235 shares), Dodge & Cox (5,372,100 shares), STATE STREET CORP (2,800,825 shares), JPMORGAN CHASE & CO (2,445,659 shares), and MORGAN STANLEY (1,880,878 shares).
This table shows the top 395 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.